Selkirk Pharma vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Contract Development & Manufacturing Organization (CDMO) — Sterile Injectables
Selkirk Pharma is a US-based CDMO specializing in aseptic fill/finish for sterile injectable drug products; raised $82M+ total; operates a 115,000 sq ft GMP facility in Spokane, WA; blueprinted a $90M expansion factory;
About
Selkirk Pharma is a contract development and manufacturing organization (CDMO) founded in 2018 by fill/finish industry veterans and headquartered in Spokane, Washington. The company was purpose-built to address the domestic shortage of aseptic fill/finish manufacturing capacity for sterile injectable drug products — a segment critical to biologics, small molecules, and parenteral medicines. Its 115,000-square-foot GMP facility at the Pacific Northwest Technology Park operates with advanced isolator technology from SKAN, Bausch and Strobel VarioSys dose-filling systems, and single-use systems designed to meet both US FDA and EU Annex 1 compliance standards.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.